Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.If you're under the age of 100, you have never lived in a world where the United States was not the most powerful nation on Earth.POMPEO BLASTS CHINA FOR CAUSING 'ENORMOUS AMOUNT OF PAIN' AND 'LOSS OF LIFE' WITH…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.When Washington bailed out the finance world more than a decade ago after the most recent financial collapse, the government set limits on CEO compensation. And they did it for a reason. Taxpayer bailouts should be used for saving…
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.All last week, we told you about Michigan Gov. Gretchen Whitmer and what she was doing in the name of science to respond to this coronavirus pandemic.NEWSOM IMPLIES COMMUNITIES NOT ALLOWED TO LIFT STAY-AT-HOME ORDERS YETShe banned the sale…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f